^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MVT-1075
i
Other names: 177Lu Human Monoclonal Antibody 5B1, 177Lu-DTPA-HuMab-5B, MVT-1075, 177Lu-CHX-A"-DTPA-HuMab-5B1, MVT 1075
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BioNTech
Drug class:
Ionizing radiation emitter, CA19-9 inhibitor
Related drugs:
2years
Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy (clinicaltrials.gov)
P1, N=7, Suspended, BioNTech Research & Development, Inc. | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Feb 2023
Trial completion date • Trial primary completion date • Combination therapy
|
CA 19-9 (Cancer antigen 19-9)
|
BNT321 • MVT-1075
over2years
Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy (clinicaltrials.gov)
P1, N=7, Suspended, BioNTech Research & Development, Inc. | Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Sep 2022
Trial completion date • Trial primary completion date • Combination therapy
|
CA 19-9 (Cancer antigen 19-9)
|
BNT321 • MVT-1075
over3years
Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy (clinicaltrials.gov)
P1, N=7, Suspended, BioNTech Research & Development, Inc. | Trial completion date: Dec 2020 --> Dec 2021 | Active, not recruiting --> Suspended | Trial primary completion date: Dec 2020 --> Dec 2021
Clinical • Trial completion date • Trial suspension • Trial primary completion date • Combination therapy
|
CA 19-9 (Cancer antigen 19-9)
|
BNT321 • MVT-1075
Share via
